UDP-003 / Cyclarity Therapeutics - LARVOL DELTA

Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Followed by an Open-label Patient Cohort (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: Cyclarity Therapeutics, Inc. | Trial completion date: Jun 2027 ➔ Dec 2027 | Trial primary completion date: Jul 2026 ➔ Dec 2026

First-in-human • Trial completion date • Trial primary completion date • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular

Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Patients (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: Cyclarity Therapeutics, Inc. | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Dec 2025 ➔ Jul 2026

First-in-human • Trial completion date • Trial primary completion date • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular

Reversal of foam cell formation by removal of 7-ketocholesterol with the cyclodextrin dimer UDP-003: a new potential drug candidate to promote atherosclerotic plaque regression. (PubMed, Atherosclerosis) - No abstract available

Journal • Atherosclerosis

Selective removal of 7-ketocholesterol by a novel atherosclerosis therapeutic candidate reverts foam cells to a macrophage-like phenotype. (PubMed, Atherosclerosis) - "Our data suggest that the targeted removal of 7KC from foam cells with UDP-003 can potentially prevent and reverse atherosclerotic plaque formation. UDP-003 has the potential to be the first disease-modifying therapeutic approach to treating atherosclerotic disease."

Journal • Atherosclerosis • Cardiovascular • CNS Disorders • Dyslipidemia • Genetic Disorders • Heart Failure • Hematological Disorders • Metabolic Disorders • Multiple Sclerosis • Sickle Cell Disease

Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Patients (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: Cyclarity Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular